A Phase 1 Clinical Trial Of Ca-4948 In Combination With Gemcitabine And Nabpaclitaxel In Metastatic Or Unresectable Pancreatic Ductal Carcinoma
Posted Date: Apr 25, 2024
- Investigator: Davendra Sohal
- Specialties: Cancer, Pancreatic Cancer
- Type of Study: Drug
This phase I trial tests the safety, side effects, and best dose of emavusertib (CA-4948) in combination with gemcitabine and nab-paclitaxel in treating patients with pancreatic ductal adenocarcinoma that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable). CA-4948 is in a class of medications called kinase inhibitors. It works by blocking the action of abnormal proteins called interleukin-1 receptor-associated kinase 4 (IRAK4) and FMS-like tyrosine kinase 3 (FLT3) that signal cells to multiply. This may help keep cancer cells from growing. The usual approach for patients with pancreatic ductal adenocarcinoma is treatment with chemotherapy drugs gemcitabine and nab-paclitaxel
Criteria:
Null
Keywords:
Pancreas, Cancer
For More Information:
Kayla Webb
NULL
cancer@uchealth.com